APTX

Aptinyx Inc. [APTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

APTX Stock Summary

Top 10 Correlated ETFs

APTX


Top 10 Correlated Stocks

APTX


In the News

01:00 26 Mar 2023 APTX

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

08:36 26 Mar 2023 APTX

Why Is Aptinyx (APTX) Stock Down 64% Today?

Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary endpoint.

07:47 26 Mar 2023 APTX

Aptinyx to Present at the SVB Securities Global Biopharma Conference

EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

09:46 26 Mar 2023 APTX

Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and CMC Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call.

07:45 26 Mar 2023 APTX

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

EVANSTON, Ill.

12:48 26 Mar 2023 APTX

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

07:13 26 Mar 2023 APTX

Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - President & Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Kathryn King - Senior Vice President, Clinical & CMC Operations Conference Call Participants Ritu Baral - Cowen Evan Hua - BMO Capital Markets Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Second Quarter 2022 Financial Results Conference Call.

07:47 26 Mar 2023 APTX

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902

07:37 26 Mar 2023 APTX

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022. A webcast recording of the presentat

12:50 26 Mar 2023 APTX

Aptinyx, Inc. (APTX) CEO Andy Kidd on Q1 2022 Results - Earnings Call Transcript

Aptinyx, Inc. (NASDAQ:APTX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Pat Flavin - IR Andy Kidd - CEO Ashish Khanna - CFO Kathryn King - SVP of Clinical and CMC operations Harald Murck - VP of Medical and Clinical Affairs Conference Call Participants Ritu Baral - Cowen Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Operator Good afternoon, and welcome to the Aptinyx First Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised the call is being recorded at the company's request.

APTX Financial details

Company Rating
Neutral
Market Cap
10.23M
Income
-37.49M
Revenue
0
Book val./share
0.72
Cash/share
0.98
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
24 Mar 2023
P/E
-0.27
Forward P/E
-
PEG
0.15
P/S
-
P/B
0.21
P/C
0.15
P/FCF
-0.12
Quick Ratio
24.72
Current Ratio
27.45
Debt / Equity
0.56
LT Debt / Equity
-
-
-
EPS (TTM)
-0.84
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-27.41%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-74.14%
SMA50
-61.54%
SMA100
-44.44%
Inst Own
42.98%
Inst Trans
-2.95%
ROA
-49%
ROE
-53%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
67.72M
Shs Float
38.42M
-
-
-
-
Target Price
1
52W Range
0.13-2.87
52W High
-
52W Low
-
RSI
34.92
Rel Volume
12.41
Avg Volume
2.37M
Volume
29.41M
Perf Week
8.32%
Perf Month
-76.62%
Perf Quarter
-58.98%
Perf Half Y
-66.44%
-
-
-
-
Beta
1.38858
-
-
Volatility
0.01%, 0.21%
Prev Close
-15.36%
Price
0.151
Change
2.03%

APTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.290.330.110.030.02
Net income per share
-1.91-2.64-1.71-1.020
Operating cash flow per share
-1.94-2.35-1.55-0.87-1.3
Free cash flow per share
-2.04-2.37-1.55-0.87-1.3
Cash per share
5.477.462.952.892.17
Book value per share
-2.367.393.022.991.94
Tangible book value per share
-2.367.393.022.991.94
Share holders equity per share
-2.367.393.022.991.94
Interest debt per share
00000
Market cap
339.99M334.09M114.76M169.08M130.47M
Enterprise value
247.85M183.45M15.91M28.05M24.35M
P/E ratio
-10.6-6.27-2-3.380
Price to sales ratio
68.5250.8231.28108.11130.47
POCF ratio
-10.39-7.04-2.2-3.99-2.06
PFCF ratio
-9.91-6.98-2.2-3.97-2.06
P/B Ratio
-8.562.241.131.161.38
PTB ratio
-8.562.241.131.161.38
EV to sales
49.9527.914.3417.9324.35
Enterprise value over EBITDA
-7.83-3.47-0.28-0.57-0.33
EV to operating cash flow
-7.57-3.87-0.31-0.66-0.38
EV to free cash flow
-7.22-3.83-0.31-0.66-0.38
Earnings yield
-0.09-0.16-0.5-0.30
Free cash flow yield
-0.1-0.14-0.45-0.25-0.49
Debt to equity
-3.450.040.050.030.21
Debt to assets
1.410.040.050.030.18
Net debt to EBITDA
2.912.851.742.841.43
Current ratio
21.7426.0421.4732.6420.18
Interest coverage
00000
Income quality
1.020.890.910.850
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.121.935.1712.460
Research and developement to revenue
6.387.4212.0820.9955.44
Intangibles to total assets
00000
Capex to operating cash flow
0.050.0100.010
Capex to revenue
-0.32-0.06-0.01-0.140.12
Capex to depreciation
-3.89-0.89-0.09-0.510.23
Stock based compensation to revenue
0.180.52.466.389.72
Graham number
10.0620.9510.788.30
ROIC
0.360.370.640.380
Return on tangible assets
-0.33-0.34-0.54-0.330
Graham Net
-2.637.172.82.791.76
Working capital
90.66M147.37M100.21M145.02M109.06M
Tangible asset value
-39.72M149.31M101.31M145.91M94.76M
Net current asset value
-42.01M146.95M99.94M144.91M94.57M
Invested capital
00000
Average receivables
712.5K757.5K511K350.5K128.5K
Average payables
1.57M1.71M1.72M1.38M915.5K
Average inventory
00000
Days sales outstanding
68.9232.0944.1759.980
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
5.311.378.266.090
Payables turnover
00000
Inventory turnover
00000
ROE
0.81-0.36-0.57-0.340
Capex per share
-0.09-0.02000

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-0.310-0.29-0.260
Operating cash flow per share
-0.27-0.28-0.24-0.22-0.51
Free cash flow per share
-0.27-0.28-0.24-0.22-0.51
Cash per share
1.851.571.481.260.98
Book value per share
1.651.41.140.920.72
Tangible book value per share
1.651.41.140.920.72
Share holders equity per share
1.651.41.140.920.72
Interest debt per share
0.2100.370.370.01
Market cap
158.46M180.8M153.72M37.78M24.93M
Enterprise value
47.2M74.68M77.85M-22.99M-41.66M
P/E ratio
-1.870-1.94-0.530
Price to sales ratio
00000
POCF ratio
-8.51-9.49-9.65-2.56-0.72
PFCF ratio
-8.51-9.55-9.65-2.56-0.72
P/B Ratio
1.411.911.980.610.51
PTB ratio
1.411.911.980.610.51
EV to sales
00000
Enterprise value over EBITDA
-2.23-3.9-4.031.362.86
EV to operating cash flow
-2.54-3.92-4.891.561.21
EV to free cash flow
-2.54-3.94-4.891.561.21
Earnings yield
-0.130-0.13-0.470
Free cash flow yield
-0.12-0.1-0.1-0.39-1.39
Debt to equity
0.180.210.380.490.56
Debt to assets
0.160.180.270.330.36
Net debt to EBITDA
5.255.553.933.64.56
Current ratio
21.0720.1822.4916.2227.45
Interest coverage
00-40.63-22.6-17.16
Income quality
0.8800.80.840.98
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0-0.01000
Capex to revenue
00000
Capex to depreciation
03.18000
Stock based compensation to revenue
00000
Graham number
3.4202.752.320
ROIC
0.1800.20.210
Return on tangible assets
-0.160-0.19-0.190
Graham Net
1.551.271.050.810.58
Working capital
126.12M109.06M101.79M86.46M71.26M
Tangible asset value
112.04M94.76M77.49M62.1M48.79M
Net current asset value
111.8M94.57M77.36M61.93M46.54M
Invested capital
0.1300.310.390
Average receivables
00000
Average payables
1.78M1.87M1.19M1.93M1.29M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.190-0.26-0.280
Capex per share
00000

APTX Frequently Asked Questions

What is Aptinyx Inc. stock symbol ?

Aptinyx Inc. is a US stock , located in Evanston of Il and trading under the symbol APTX

Is Aptinyx Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $1. The lowest prediction is $1 and the highest is $1

What is APTX stock prediction ?

What is Aptinyx Inc. stock quote today ?

Aptinyx Inc. stock price is $0.151 today.

Is Aptinyx Inc. stock public?

Yes, Aptinyx Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap